These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32614274)

  • 1. Impact of Time to Surgery and Surgical Delay on Oncologic Outcomes for Renal Cell Carcinoma.
    Shiff B; Breau RH; Patel P; Mallick R; Tanguay S; So A; Lavallée L; Moore R; Rendon R; Kapoor A; Pouliot F; Finelli A; Bhindi B; Lattouf JB; Basappa N; Wood L; Heng D; Bjarnason G; Drachenberg D
    J Urol; 2021 Jan; 205(1):78-85. PubMed ID: 32614274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Percutaneous Ablation Versus Robotic Partial Nephrectomy in the Treatment of cT1b Renal Tumors: Oncologic and Functional Outcomes of a Propensity Score-weighted Analysis.
    Rembeyo G; Correas JM; Jantzen R; Audenet F; Dariane C; Delavaud C; Mejean A; Timsit MO
    Clin Genitourin Cancer; 2020 Apr; 18(2):138-147. PubMed ID: 31982346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing Outcomes for Patients with Clinical T1b Renal Cell Carcinoma Treated With Either Percutaneous Microwave Ablation or Surgery.
    Shapiro DD; Wells SA; Best SL; Hedican SP; Ziemlewicz TJ; Lubner MG; Hinshaw JL; Lee FT; Jarrard DF; Richards KA; Downs TM; Allen GO; Nakada SY; Abel EJ
    Urology; 2020 Jan; 135():88-94. PubMed ID: 31585198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positive Surgical Margins Increase Risk of Recurrence after Partial Nephrectomy for High Risk Renal Tumors.
    Shah PH; Moreira DM; Okhunov Z; Patel VR; Chopra S; Razmaria AA; Alom M; George AK; Yaskiv O; Schwartz MJ; Desai M; Vira MA; Richstone L; Landman J; Shalhav AL; Gill I; Kavoussi LR
    J Urol; 2016 Aug; 196(2):327-34. PubMed ID: 26907508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk Factors for Upstaging, Recurrence, and Mortality in Clinical T1-2 Renal Cell Carcinoma Patients Upstaged to pT3a Disease: An International Analysis Utilizing the 8th Edition of the Tumor-Node-Metastasis Staging Criteria.
    Hamilton ZA; Capitanio U; Pruthi D; Ghali F; Larcher A; Patel DN; Eldefrawy A; Patel S; Cotta BH; Bradshaw AW; Meagher MF; Miller NS; Carenzi C; Wan F; Liss MA; McGregor T; Montorsi F; Derweesh IH
    Urology; 2020 Apr; 138():60-68. PubMed ID: 31836465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mortality Increases When Radical Nephrectomy is Delayed More Than 60 Days for T3 Renal Cell Carcinoma.
    Zhao F; Liu X; Zhang C; Zhu H; Qi N
    Technol Cancer Res Treat; 2021; 20():15330338211043963. PubMed ID: 34595976
    [No Abstract]   [Full Text] [Related]  

  • 7. Positive surgical margin following radical nephrectomy is an independent predictor of local recurrence and disease-specific survival.
    Abu-Ghanem Y; Ramon J; Berger R; Kaver I; Fridman E; Leibowitz-Amit R; Dotan ZA
    World J Surg Oncol; 2017 Nov; 15(1):193. PubMed ID: 29096642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Partial Nephrectomy is Associated with Higher Risk of Relapse Compared with Radical Nephrectomy for Clinical Stage T1 Renal Cell Carcinoma Pathologically Up Staged to T3a.
    Shah PH; Moreira DM; Patel VR; Gaunay G; George AK; Alom M; Kozel Z; Yaskiv O; Hall SJ; Schwartz MJ; Vira MA; Richstone L; Kavoussi LR
    J Urol; 2017 Aug; 198(2):289-296. PubMed ID: 28274620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal cell carcinoma in the solitary kidney: an analysis of complications and outcome after nephron sparing surgery.
    Ghavamian R; Cheville JC; Lohse CM; Weaver AL; Zincke H; Blute ML
    J Urol; 2002 Aug; 168(2):454-9. PubMed ID: 12131287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does renal tumor biopsies for small renal carcinoma increase the risk of upstaging on final surgery pathology report and the risk of recurrence?
    Asselin C; Finelli A; Breau RH; Mallick R; Kapoor A; Rendon RA; Tanguay S; Pouliot F; Fairey A; Lavallée LT; Bladou F; Kawakami J; So AI; Richard PO
    Urol Oncol; 2020 Oct; 38(10):798.e9-798.e16. PubMed ID: 32693974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncologic outcomes of patients with positive surgical margin after partial nephrectomy: a 25-year single institution experience.
    Petros FG; Metcalfe MJ; Yu KJ; Keskin SK; Fellman BM; Chang CM; Gu C; Tamboli P; Matin SF; Karam JA; Wood CG
    World J Urol; 2018 Jul; 36(7):1093-1101. PubMed ID: 29488096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies.
    Mir MC; Derweesh I; Porpiglia F; Zargar H; Mottrie A; Autorino R
    Eur Urol; 2017 Apr; 71(4):606-617. PubMed ID: 27614693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five-year Oncologic Outcomes After Transperitoneal Robotic Partial Nephrectomy for Renal Cell Carcinoma.
    Andrade HS; Zargar H; Caputo PA; Akca O; Kara O; Ramirez D; Haber GP; Stein RJ; Kaouk JH
    Eur Urol; 2016 Jun; 69(6):1149-54. PubMed ID: 26719014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pattern, timing and predictors of recurrence after surgical resection of chromophobe renal cell carcinoma.
    Neves JB; Vanaclocha Saiz L; Abu-Ghanem Y; Marchetti M; Tran-Dang MA; El-Sheikh S; Barod R; Beisland C; Capitanio U; Cullen D; Klatte T; Ljungberg B; Mumtaz F; Patki P; Stewart GD; Dabestani S; Tran MGB; Bex A;
    World J Urol; 2021 Oct; 39(10):3823-3831. PubMed ID: 33851271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cryoablation versus Partial Nephrectomy for Clinical T1b Renal Tumors: A Matched Group Comparative Analysis.
    Caputo PA; Zargar H; Ramirez D; Andrade HS; Akca O; Gao T; Kaouk JH
    Eur Urol; 2017 Jan; 71(1):111-117. PubMed ID: 27568064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgical margin does not influence recurrence rate in pT1 clear cell renal cell carcinoma after partial nephrectomy: A multicenter study.
    Kang HW; Lee SK; Kim WT; Yun SJ; Lee SC; Kim WJ; Hwang EC; Kang SH; Hong SH; Chung J; Kwon TG; Kim HH; Kwak C; Byun SS; Kim YJ;
    J Surg Oncol; 2016 Jul; 114(1):70-4. PubMed ID: 27074886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histologic subtype needs to be considered after partial nephrectomy in patients with pathologic T1a renal cell carcinoma: papillary vs. clear cell renal cell carcinoma.
    Yoo S; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Kim CS
    J Cancer Res Clin Oncol; 2017 Sep; 143(9):1845-1851. PubMed ID: 28451753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of bilaterality, pathological features and surgical outcome in nonhereditary renal cell carcinoma.
    Blute ML; Itano NB; Cheville JC; Weaver AL; Lohse CM; Zincke H
    J Urol; 2003 Apr; 169(4):1276-81. PubMed ID: 12629342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Perioperative Infection on Cancer Specific Survival after Nephrectomy for Renal Cell Carcinoma.
    Tallman JE; Pearce SM; Kuchta K; Helfand BT; Eggener SE
    J Urol; 2017 Nov; 198(5):1027-1032. PubMed ID: 28551443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Female Gender Predicts Favorable Prognosis in Patients With Non-metastatic Clear Cell Renal Cell Carcinoma Undergoing Curative Surgery: Results From the International Marker Consortium for Renal Cancer (INMARC).
    Fukushima H; Saito K; Yasuda Y; Tanaka H; Patil D; Cotta BH; Patel SH; Master VA; Derweesh IH; Fujii Y
    Clin Genitourin Cancer; 2020 Apr; 18(2):111-116.e1. PubMed ID: 32001181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.